|Data Show Medtronic Quadripolar CRT Technology Optimizes Treatment for Heart Failure Patients|
Positive Results from Two Studies Featured at Heart Rhythm Society 36th Annual Scientific Sessions
DUBLIN and BOSTON - MAY 18, 2015 -Medtronic plc (NYSE: MDT) today announced study results demonstrating that its quadripolar cardiac resynchronization therapy (CRT) system gives physicians more options to optimize CRT delivery, which may improve heart failure patients' response to the therapy. During Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston, data from the Attain® Performa® Quadripolar Lead Clinical Study revealed the clinical benefits associated with steroid on all four electrodes. A separate analysis demonstrated the importance of assessing pacing vectors over time. VectorExpress(TM) technology, an easy-to-use tool found on Medtronic Viva® Quad CRT-defibrillators, provides clinically actionable information to help physicians select and maintain the optimal pacing configurations - at implant and in follow-up visits - for each patient, in only two minutes.
"When physicians pair Attain Performa leads with Viva Quad devices and the AdaptivCRT technology to treat their heart failure patients, they have more options to optimize therapy delivery and personalize treatment," said David Steinhaus, M.D., vice president and general manager, Heart Failure, and medical director for the Cardiac Rhythm and Heart Failure business, which is part of the Cardiac and Vascular Group at Medtronic. "These new data support the clinical benefits of CRT technology and add to the body of evidence supporting Medtronic quadripolar leads and CRT devices as an important therapy option for patients with heart failure."
Effectiveness of Steroid-Eluting Electrodes on Quadripolar LV Leads
Steroid on all electrodes led to a statistically significant reduction in PCTs compared to leads without steroid on all electrodes (p<0.0001). These lower thresholds give physicians more usable options to achieve optimal pacing while improving longevity.
"While we have known that steroid-eluting electrodes on cardiac leads
Serial Post-Implant LV Vector Selection and Device Longevity
"We are just beginning to understand the potential value of advancements in resynchronization therapy like quadripolar LV leads and automated software tools. For example, the VectorExpress tool offers robust method of assessing pacing capture and impedance data from all 16 vectors of a quadripolar lead in under 3 minutes," said Derek Exner, M.D., Professor, Libin Cardiovascular Institute of Alberta, Canada. "Using this VectorExpress data we can substantially enhance battery longevity and improve patient outcomes."
About the Attain Performa® Quadripolar Lead Portfolio and Viva CRT-Ds
All three Attain Performa leads are compatible with the company's newest portfolio of CRT devices, the Viva Quad XT and Viva Quad S CRT-D systems. The Viva Quad XT CRT-D also features the AdaptivCRT® algorithm. Recent data from a study published in the Journal of the American College of Cardiology: Heart Failure showed that the AdaptivCRT algorithm was associated with a significant relative reduction in both all cause 30-day readmissions (46 percent) and heart failure 30-day readmissions (59 percent), when compared to echo-optimized CRT.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
- end -
i Biffi et al. Effort of Bipolar Electrode Spacing on Phrenic Nerve Stimulation and Left Ventricular Pacing Thresholds: An Acute Canine Study. Circulation Arrhythmia and Electrophysiology. 2012.